Is lifelong rifaximin therapy recommended for preventing recurrent diverticulitis?

Rifaximin for Diverticulitis Prevention: Not Recommended for Lifelong Use

No, patients should not remain on rifaximin for life for diverticulitis prevention—the American Gastroenterological Association explicitly recommends against routine rifaximin use after acute uncomplicated diverticulitis. 1

Primary Guideline Recommendation

The AGA provides a conditional recommendation against the use of rifaximin after acute uncomplicated diverticulitis, based on very low-quality evidence. 1 This recommendation stems from:

• Lack of statistically significant benefit: The single unblinded trial evaluating rifaximin was terminated early and showed only a numerical (not statistically significant) reduction in recurrence rates. 1
• Uncertain efficacy: The effect of rifaximin remains uncertain despite potential benefits, particularly when weighed against costs and potential adverse events. 1
• No FDA approval for this indication: Rifaximin is FDA-approved for travelers' diarrhea, hepatic encephalopathy, and IBS-D with specific dosing regimens (14 days for IBS-D with up to 2 retreatments), but not for diverticulitis prevention. 2

The 2022 American College of Physicians guideline reinforces this position, noting insufficient evidence for rifaximin in preventing recurrent diverticulitis. 1

Clinical Context and Duration Considerations

When Rifaximin Has Been Studied

Research studies have examined cyclic rifaximin therapy (not continuous lifelong treatment) with regimens such as:

• 7-10 days per month for 12 months 3, 4
• Monthly cycles showing symptom reduction over 6-12 months 5, 4
• Long-term use up to 8 years in observational studies 6

Important distinction: These studies evaluated intermittent cyclic therapy for symptomatic uncomplicated diverticular disease (SUDD), not continuous lifelong prophylaxis after acute diverticulitis. 7, 8

Evidence Quality Issues

• Most supporting data comes from observational studies and retrospective analyses, not high-quality randomized controlled trials. 9, 5, 10
• The Italian Society of Gastroenterology notes that cyclic rifaximin use is "promising" for preventing diverticulitis recurrence but emphasizes the "low therapeutic advantage needs to be verified." 8
• No evidence exists for rifaximin efficacy in treating acute uncomplicated diverticulitis itself. 7, 8

What Should Be Recommended Instead

Evidence-Based Alternatives (Stronger Recommendations)

Lifestyle modifications have better supporting evidence: 1

• High-fiber diet or fiber supplementation (conditional recommendation, though very low-quality evidence) 1
• Vigorous physical activity (conditional recommendation) 1
• Avoid nonaspirin NSAIDs if possible (conditional recommendation) 1
• Maintain normal body mass index 1
• Smoking cessation 1

Mesalamine Is Explicitly Not Recommended

The AGA provides a strong recommendation against mesalamine after acute uncomplicated diverticulitis (moderate-quality evidence)—this is one of the few strong recommendations in diverticulitis management. 1 The ACP 2022 guideline confirms this with high-certainty evidence showing no benefit. 1

Common Pitfalls to Avoid

1. Confusing symptomatic uncomplicated diverticular disease (SUDD) with acute diverticulitis: Some European studies support rifaximin for chronic SUDD symptoms, but this is different from preventing acute diverticulitis recurrence. 8, 10

2. Assuming "cyclic" means "lifelong": Published cyclic regimens typically span 6-12 months, not indefinite duration. 3, 4

3. Extrapolating from IBS-D data: While rifaximin is FDA-approved for IBS-D with a specific retreatment protocol (up to 2 additional 14-day courses), this does not translate to diverticulitis prevention. 2

4. Geographic practice variation: Rifaximin is commonly used for diverticular disease in Italy and some European countries, but this does not align with current U.S. guideline recommendations. 8, 10

Surgical Considerations

For patients with persistent or frequently recurring uncomplicated diverticulitis or complicated diverticulitis, elective surgery should be discussed as a personalized decision considering severity, patient preferences, and individual risk-benefit profile—not based solely on number of episodes. 1 Surgery shows high-certainty evidence for reducing recurrence rates, though balanced against perioperative risks. 1